Decitabine in the treatment of acute myeloid leukemia in elderly patients.

Cancer Manag Res · 2014 · PMC3917925 · PMID 24520204

Europe PMC DOI

hedged sentences

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significanceP =0.16not close (p > 0.1)

Decitabine therapy was also associated with a trend towards longer time to AML progression or death (median 12.1 vs 7.8 months), but this did not reach statistical significance ( P =0.16).

also in 111,027 other papers

failed to reach significanceno p-value reported

A recent phase III study demonstrated higher rates of complete remission with decitabine therapy compared to low-dose cytarabine in elderly AML patients, but the survival difference failed to reach significance. 44 , 45 At present, the role of decitabine in the treatment of elderly AML patients is yet to be fully defined.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.